v3.26.1
SEGMENT REPORTING - Summary of Significant Research and Development and General and Administrative Expense to CODM (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]            
Revenue $ 0   $ 18   $ 10,838 $ 47
Platform development and early-stage research expenses:            
Depreciation and amortization         552 773
Total research and development expenses 12,394   12,768   25,504 26,356
General and administrative expense            
Total general and administrative expenses 6,767   9,127   13,570 17,680
Total operating expenses 19,161   21,895   39,074 44,036
Operating loss (19,161)   (21,877)   (28,236) (43,989)
Total other expense (13,491)   (1,643)   (22,857) (96)
Net (loss) income (32,652) $ (18,441) (23,520) $ (20,565) (51,093) (44,085)
Operating Segment            
Segment Reporting [Line Items]            
Revenue 0   18   10,838 47
Platform development and early-stage research expenses:            
Employee-related costs (including share-based compensation) 4,733   4,766   9,239 10,066
Laboratory supplies and services 309   570   682 1,108
CMOs and outsourced research and development 204   239   257 2,348
Facility-related costs, laboratory equipment, and maintenance 600   807   1,346 1,535
Depreciation and amortization 229   330   505 670
Licensing fees and other research and development costs 29   515   1,352 1,049
Total research and development expenses 12,394   12,768   25,504 26,356
General and administrative expense            
Employee-related costs (including share-based compensation) 3,986   5,730   7,814 11,190
Consulting and professional services 1,500   1,665   2,936 3,201
Other operating expenses and all other costs 1,281   1,732   2,820 3,289
Total general and administrative expenses 6,767   9,127   13,570 17,680
Total operating expenses 19,161   21,895   39,074 44,036
Operating loss (19,161)   (21,877)   (28,236) (43,989)
Total other expense (13,491)   (1,643)   (22,857) (96)
(Loss) income from operations         (51,093) (44,085)
Net (loss) income (32,652)   (23,520)   (51,093) (44,085)
PBGENE-HBV external development costs | Operating Segment            
Direct research and development expenses by product candidate:            
External development costs (credits) 2,031   1,378   3,866 2,979
PBGENE-DMD external development costs | Operating Segment            
Direct research and development expenses by product candidate:            
External development costs (credits) $ 4,259   $ 4,163   $ 8,257 $ 6,601